Salah Al-Batran, Prof. Dr.
Institut für Klinische Krebsforschung IKF GmbH · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Salah Al-Batran, Prof. Dr. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07387198 · Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy · study director
- Ph2NCT07260175 · Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Cholangiocarcinoma, IDH Mutation · study director
- Ph1/Ph2NCT06731803 · Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · active not recruiting · Esophagogastric Adenocarcinoma · study director
- Ph2NCT06722183 · Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor EntitiesInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Colorectal Cancer · study director
- Ph1/Ph2NCT06123468 · Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Esophagogastric Adenocarcinoma · study director
- Ph2NCT05504720 · Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Esophagogastric Adenocarcinoma · study director
- Ph2NCT05239169 · Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.